Cardiovascular

Bevyxxa—VTE Protection From Hospital to Home

VTE events in acute medically ill patients are associated with high mortality, morbidity, and cost, and are largely preventable with effective pharmacologic prophylaxis. But before Bevyxxa, there was no anticoagulant VTE prophylaxis for these patients in the first 30 days after hospital discharge, when VTE risk is highest.

Our unbranded campaign created awareness of the unmet need and bridged to our branded launch campaign. The branded campaign introduces Bevyxxa into the market and creates awareness of the unique benefits of the drug—the first oral anticoagulant for extended prophylaxis of VTE in the medically ill patient.

Work
Brand ID
Campaign: Unbranded + Branded
Website
Convention
Print